Home
|
Job-opportunities
|
Contact
|
News
|
Donate
Overview
DNDi Worldwide
Business Model
Stakeholders
Friends of DNDi
Our People
Annual Report
DNDi's Policies
Endorsements
Letter from Chairman and Executive Director
Diseases
Portfolio
R&D Organisation
Building Portfolio
Clinical Trial Protocols
Open Innovation
ASAQ
ASMQ
NECT
SSG&PM
Paediatric Benznidazole
LEAP Platform
HAT Platform
Chagas Platform
Technology transfer ASMQ
Technology transfer ASAQ
Global
Access
IP
Regulatory
Sustainable Funding
Press Kit
Press Releases
Press Articles
Scientific Publications
Newsletters
Outlooks
Multimedia
Events
Press Room
Business Model
Partners
IP & Licensing Policies
To Become a DNDi Partner
How to help
Donors
Key Financial Figures
Fundraising Policy
Donate
Home
Diseases
Human African Trypanosomiasis
Portfolio
Diseases
Human African Trypanosomiasis
Leishmaniasis
Chagas
Malaria
Paediatric HIV
Helminth infections
Project Portfolio
R&D Organisation
Building Portfolio
Clinical Trial Protocols
Open Innovation
Portfolio
Portfolio
By 2014, DNDi aims to deliver from its HAT-specific portfolio:
1 new combination therapy recommended by WHO
1 new drug registered
A robust pipeline
For more details on each project, see DND
i
's
Global Portfolio
HAT
Global View
Disease Background
Current Treatments
DNDi Strategy
Target Product Profile
Portfolio
Clinical Trial Platform
Clinical Trial Protocols
Related Publications
SITEMAP
DISCLAIMER
PRIVACY
Except where otherwise noted, content on this site is licensed under
a Creative Commons Attribution-Noncommercial-Share Alike 2.5 Switzerland License